Abstract
ObjectivePrevious reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with psoriatic arthritis (PsA), including patients with prior antitumour necrosis factor (TNF)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have